drugset / Trial / NCT06429137

A Study in Healthy Men to Test How Well Different Doses of BI 3731579 Are Tolerated

NCT06429137

Phase 1 Completed 63 enrolled Boehringer Ingelheim
RandomizedParallel-groupSingle-blindTreatment

Summary

The main objectives of this trial are to investigate safety, tolerability and pharmacokinetics (PK) of BI 3731579 in healthy male subjects.

Timeline

Start
2024-07-08
Primary completion
2025-05-19
Completion
2025-05-27

Drugs

EvaluationDrugModalityDoseRoute
Subject BI 3731579 Unknown

Indications

No indication recorded.